Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma

Table 3

Cross-trial comparison.

	V325		REAL-2
	DCF	CF	ECF	ECX	EOF	EOX	DOX
Median age (yr)	55	55	65	64	61	62	48
Range (yr)	26~79	25~76	22~83	25~82	33~78	25~80	27~72
Metastasis (%)	96	97	79.5	76.8	77	75.7	83.8
One least dose reduction (%)	41.2	36.2	/	/	/	/	43.2
OS (m)	9.2	8.6	9.9	9.9	9.3	11.2	11.9
PFS (m)	5.6	3.7	6.2	6.7	6.5	7	6.5
RR (%)	37	25	40.7	46.4	42.4	47.9	29.7
CR (%)	2	1	4.1	4.2	2.6	3.9	2.7
PR (%)	35	24	36.6	42.2	39.8	44	27
SD (%)	30	31	/	/	/	/	62.2
Adverse events
Leukopenia	65	31	/	/	/	/	37.8
Neutropenia	82	57	41.7	51.1	29.9	27.6	37.8
Fabric neutropenia	29	12	9.3	6.7	8.5	7.8	10.8
Hand-foot syndrome	/	/	4.3	10.3	2.7	3.1	8.1
Nausea	14	17	10.2	7.7	13.8	11.4	5.4
Vomit	14	17					5.4
Diarrhea	19	8	2.6	5.1	10.7	11.9	2.7
Fatigue	19	14	16	15.5	12.9	24.9	27